ID

24577

Descrizione

Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00510887

collegamento

https://clinicaltrials.gov/show/NCT00510887

Keywords

versioni (1)
  1. 07/08/17 07/08/17 -
Caricato su

7 agosto 2017

DOI

Per favore, per richiedere un accesso.

Licenza

Creative Commons BY 4.0
Commenti del modello :

Puoi commentare il modello dati qui. Tramite i fumetti nei gruppi di articoli e articoli è possibile aggiungere commenti a quelli in modo specifico.

Torna ai commenti del modello
Commenti del gruppo di articoli per :

Commenti dell'articolo per :

Per scaricare i modelli di dati devi essere registrato. Per favore accesso o registrati GRATIS.

Eligibility Lymphoma, Follicular NCT00510887

Inglese

Eligibility Lymphoma, Follicular NCT00510887

1 moduli  
Inclusion Criteria
Descrizione

Inclusion Criteria

Alias
UMLS CUI
C1512693
diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen.
Descrizione

Follicular Lymphoma Ann Arbor lymphoma staging system | Therapeutic procedure Quantity | Persistent Disease | Recurrent disease | Refractory Disease

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0024301
UMLS CUI [1,2]
C0432516
UMLS CUI [2,1]
C0087111
UMLS CUI [2,2]
C1265611
UMLS CUI [3]
C2983415
UMLS CUI [4]
C0277556
UMLS CUI [5]
C1514815
no prior bortezomib therapy.
Descrizione

Bortezomib Absent

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C1176309
UMLS CUI [1,2]
C0332197
voluntary written informed consent.
Descrizione

Informed Consent

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0021430
female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.
Descrizione

Postmenopausal state | Female Sterilization | Gender Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2]
C0015787
UMLS CUI [3,1]
C0079399
UMLS CUI [3,2]
C0700589
male subject agrees to use an acceptable method for contraception for the duration of the study therapy.
Descrizione

Gender Contraceptive methods

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0079399
UMLS CUI [1,2]
C0700589
18 years of age or older.
Descrizione

Age

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0001779
aspartate aminotransferase (ast),alanine aminotransferase (alt), total bilirubin < 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma.
Descrizione

Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Exclusion Measurement Secondary to Lymphoma

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0201899
UMLS CUI [2]
C0201836
UMLS CUI [3]
C1278039
UMLS CUI [4,1]
C2828389
UMLS CUI [4,2]
C0242485
UMLS CUI [4,3]
C0175668
UMLS CUI [4,4]
C0024299
eastern cooperative oncology group (ecog) performance status 0-2.
Descrizione

ECOG performance status

Tipo di dati

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Descrizione

Exclusion Criteria

Alias
UMLS CUI
C0680251
platelet count of < 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease.
Descrizione

Platelet Count measurement | Exclusion Platelet count Due to Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032181
UMLS CUI [2,1]
C2828389
UMLS CUI [2,2]
C1287267
UMLS CUI [2,3]
C0678226
UMLS CUI [2,4]
C0012634
absolute neutrophil count of < 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease.
Descrizione

Absolute neutrophil count | Exclusion ANC Due to Disease

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0948762
UMLS CUI [2,1]
C2828389
UMLS CUI [2,2]
C0948762
UMLS CUI [2,3]
C0678226
UMLS CUI [2,4]
C0012634
estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment.
Descrizione

Estimation of creatinine clearance by Cockcroft-Gault formula | Creatinine clearance measurement

Tipo di dati

boolean

Alias
UMLS CUI [1]
C2711451
UMLS CUI [2]
C0373595
≥grade 2 peripheral neuropathy within 14 days before enrollment.
Descrizione

Peripheral Neuropathy CTCAE Grades

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
myocardial infarction within 6 months prior to enrollment or has new york hospital association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
Descrizione

Myocardial Infarction | Heart failure New York Heart Association Classification | Angina Pectoris Uncontrolled | Ventricular arrhythmia Uncontrolled Severe | Ischemia Electrocardiography

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0027051
UMLS CUI [2,1]
C0018801
UMLS CUI [2,2]
C1275491
UMLS CUI [3,1]
C0002962
UMLS CUI [3,2]
C0205318
UMLS CUI [4,1]
C0085612
UMLS CUI [4,2]
C0205318
UMLS CUI [4,3]
C0205082
UMLS CUI [5,1]
C0022116
UMLS CUI [5,2]
C1623258
patient has hypersensitivity to boron, mannitol or any drug included in the current protocol.
Descrizione

Hypersensitivity Boron | Mannitol allergy | Hypersensitivity Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0020517
UMLS CUI [1,2]
C0006030
UMLS CUI [2]
C0571922
UMLS CUI [3,1]
C0020517
UMLS CUI [3,2]
C0013230
female subject is pregnant or lactating.
Descrizione

Pregnancy | Breast Feeding

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0032961
UMLS CUI [2]
C0006147
received other investigational drugs for this disease within 14 days of enrollment
Descrizione

Investigational New Drugs

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0013230
serious medical or psychiatric illness likely to interfere with participation in this clinical study.
Descrizione

Illness Serious Interferes with Study Subject Participation Status | Serious mental illness Interferes with Study Subject Participation Status

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0221423
UMLS CUI [1,2]
C0205404
UMLS CUI [1,3]
C0521102
UMLS CUI [1,4]
C2348568
UMLS CUI [2,1]
C3841614
UMLS CUI [2,2]
C0521102
UMLS CUI [2,3]
C2348568
known hiv+ status.
Descrizione

HIV Seropositivity

Tipo di dati

boolean

Alias
UMLS CUI [1]
C0019699
cardiac ejection fraction less than 35% at study entry measured by echocardiogram, multigated acquisition (muga) or cardiac mri.
Descrizione

Cardiac ejection fraction Echocardiography | Cardiac ejection fraction Multiple gated acquisition scanning | Cardiac ejection fraction MRI of Heart

Tipo di dati

boolean

Alias
UMLS CUI [1,1]
C0232174
UMLS CUI [1,2]
C0013516
UMLS CUI [2,1]
C0232174
UMLS CUI [2,2]
C0521317
UMLS CUI [3,1]
C0232174
UMLS CUI [3,2]
C0412692
Ritorna all'inizio della pagina

Similar models

Eligibility Lymphoma, Follicular NCT00510887

1 moduli
Name
genere
Description | Question | Decode (Coded Value)
Tipo di dati
Alias
Item Group
C1512693 (UMLS CUI)
Follicular Lymphoma Ann Arbor lymphoma staging system | Therapeutic procedure Quantity | Persistent Disease | Recurrent disease | Refractory Disease
Item
diagnosis of grade 1-3 follicular lymphoma with persistent, relapsed, or refractory disease to at least one prior regimen.
boolean
C0024301 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
C0087111 (UMLS CUI [2,1])
C1265611 (UMLS CUI [2,2])
C2983415 (UMLS CUI [3])
C0277556 (UMLS CUI [4])
C1514815 (UMLS CUI [5])
Bortezomib Absent
Item
no prior bortezomib therapy.
boolean
C1176309 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
Informed Consent
Item
voluntary written informed consent.
boolean
C0021430 (UMLS CUI [1])
Postmenopausal state | Female Sterilization | Gender Contraceptive methods
Item
female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control.
boolean
C0232970 (UMLS CUI [1])
C0015787 (UMLS CUI [2])
C0079399 (UMLS CUI [3,1])
C0700589 (UMLS CUI [3,2])
Gender Contraceptive methods
Item
male subject agrees to use an acceptable method for contraception for the duration of the study therapy.
boolean
C0079399 (UMLS CUI [1,1])
C0700589 (UMLS CUI [1,2])
Age
Item
18 years of age or older.
boolean
C0001779 (UMLS CUI [1])
Aspartate aminotransferase measurement | Alanine aminotransferase measurement | Serum total bilirubin measurement | Exclusion Measurement Secondary to Lymphoma
Item
aspartate aminotransferase (ast),alanine aminotransferase (alt), total bilirubin < 3 times the upper limit of normal unless documented by the treating physician to be secondary to underlying lymphoma.
boolean
C0201899 (UMLS CUI [1])
C0201836 (UMLS CUI [2])
C1278039 (UMLS CUI [3])
C2828389 (UMLS CUI [4,1])
C0242485 (UMLS CUI [4,2])
C0175668 (UMLS CUI [4,3])
C0024299 (UMLS CUI [4,4])
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status 0-2.
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
Platelet Count measurement | Exclusion Platelet count Due to Disease
Item
platelet count of < 50,000 within 14 days before enrollment unless documented by the treating physician to be due to the disease.
boolean
C0032181 (UMLS CUI [1])
C2828389 (UMLS CUI [2,1])
C1287267 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0012634 (UMLS CUI [2,4])
Absolute neutrophil count | Exclusion ANC Due to Disease
Item
absolute neutrophil count of < 1000 within 14 days before enrollment unless documented by the treating physician to be due to disease.
boolean
C0948762 (UMLS CUI [1])
C2828389 (UMLS CUI [2,1])
C0948762 (UMLS CUI [2,2])
C0678226 (UMLS CUI [2,3])
C0012634 (UMLS CUI [2,4])
Estimation of creatinine clearance by Cockcroft-Gault formula | Creatinine clearance measurement
Item
estimated or measured creatinine clearance of less than 30 ml/min within 14 days before enrollment.
boolean
C2711451 (UMLS CUI [1])
C0373595 (UMLS CUI [2])
Peripheral Neuropathy CTCAE Grades
Item
≥grade 2 peripheral neuropathy within 14 days before enrollment.
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Myocardial Infarction | Heart failure New York Heart Association Classification | Angina Pectoris Uncontrolled | Ventricular arrhythmia Uncontrolled Severe | Ischemia Electrocardiography
Item
myocardial infarction within 6 months prior to enrollment or has new york hospital association (nyha) class iii or iv heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia.
boolean
C0027051 (UMLS CUI [1])
C0018801 (UMLS CUI [2,1])
C1275491 (UMLS CUI [2,2])
C0002962 (UMLS CUI [3,1])
C0205318 (UMLS CUI [3,2])
C0085612 (UMLS CUI [4,1])
C0205318 (UMLS CUI [4,2])
C0205082 (UMLS CUI [4,3])
C0022116 (UMLS CUI [5,1])
C1623258 (UMLS CUI [5,2])
Hypersensitivity Boron | Mannitol allergy | Hypersensitivity Investigational New Drugs
Item
patient has hypersensitivity to boron, mannitol or any drug included in the current protocol.
boolean
C0020517 (UMLS CUI [1,1])
C0006030 (UMLS CUI [1,2])
C0571922 (UMLS CUI [2])
C0020517 (UMLS CUI [3,1])
C0013230 (UMLS CUI [3,2])
Pregnancy | Breast Feeding
Item
female subject is pregnant or lactating.
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Investigational New Drugs
Item
received other investigational drugs for this disease within 14 days of enrollment
boolean
C0013230 (UMLS CUI [1])
Illness Serious Interferes with Study Subject Participation Status | Serious mental illness Interferes with Study Subject Participation Status
Item
serious medical or psychiatric illness likely to interfere with participation in this clinical study.
boolean
C0221423 (UMLS CUI [1,1])
C0205404 (UMLS CUI [1,2])
C0521102 (UMLS CUI [1,3])
C2348568 (UMLS CUI [1,4])
C3841614 (UMLS CUI [2,1])
C0521102 (UMLS CUI [2,2])
C2348568 (UMLS CUI [2,3])
HIV Seropositivity
Item
known hiv+ status.
boolean
C0019699 (UMLS CUI [1])
Cardiac ejection fraction Echocardiography | Cardiac ejection fraction Multiple gated acquisition scanning | Cardiac ejection fraction MRI of Heart
Item
cardiac ejection fraction less than 35% at study entry measured by echocardiogram, multigated acquisition (muga) or cardiac mri.
boolean
C0232174 (UMLS CUI [1,1])
C0013516 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2,1])
C0521317 (UMLS CUI [2,2])
C0232174 (UMLS CUI [3,1])
C0412692 (UMLS CUI [3,2])
Ritorna all'inizio della pagina 

Contatto

Si prega di utilizzare questo modulo per feedback, domande e suggerimenti per miglioramenti.

I campi contrassegnati da * sono obbligatori.

Aiuto

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial